Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism [23]

New England Journal of Medicine

Volumn 355, Issue 23, 2006, Pages 2494-2495

  Grey, Andrew ^a   O'Sullivan, Susannah ^a   Reid, Ian R ^a   Browett, Peter ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BCR ABL PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; IMATINIB; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE;

BLOOD SAMPLING; BONE REMODELING; BONE TURNOVER; CALCIUM DEFICIENCY; CALCIUM METABOLISM; CHRONIC MYELOID LEUKEMIA; DIET RESTRICTION; DOSE RESPONSE; DRUG INHIBITION; ENDOCRINE DISEASE; GENE MUTATION; HUMAN; HYPOPHOSPHATEMIA; INFORMATION PROCESSING; INFORMED CONSENT; INTESTINE ABSORPTION; KIDNEY TUBULE; LETTER; MEDICAL ETHICS; OSSIFICATION; OSTEOLYSIS; PHOSPHATURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; URINALYSIS;

ADULT; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PYRIMIDINES;

EID: 33845452829     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062388     Document Type: Letter

References (3)

1. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13.
2. Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107:4334-7.
3. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.